ANAB · AnaptysBio, Inc.
AnaptysBio Inc (ANAB)
What's happening
- ANAB is up 0.90% today, trading at $55.88. — Live quote
- Volume today (21,010) is well below its 3-month average of 600,970. (Finnhub fundamentals)
- Reports earnings on 2026-09-11 (after market close), 8 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-1.84 actual vs. $-0.62 estimated (-198.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-09-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 |
|---|---|---|---|---|---|
| Market cap | $1.06B | $592.9M | $425.8M | $380.4M | $214.4M |
| P/E | -9.19 | -6.20 | -2.70 | -2.34 | -1.33 |
| Price/Sales | 7.00 | 3.79 | 4.68 | 5.01 | 4.16 |
| Price/Book | 83.45 | -20.16 | -9.52 | 11.18 | 2.54 |
| EV/Revenue | 5.37 | 3.09 | 4.19 | 3.71 | 0.44 |
| EV/EBITDA | -15.36 | -11.73 | -3.28 | — | — |
| ROE | -907.90% | 325.32% | 352.02% | -478.46% | -190.54% |
| ROA | -35.10% | -27.10% | -46.97% | -38.57% | -32.58% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +271.8%. Finnhub market metrics ↗
- Latest SEC filing is Form 8-K, filed 2026-08-11; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -8.0% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -11.5%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ANAB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Sep '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.6M | $76.3M | $22.3M | $27.8M | $30.0M | $11.0M | $7.2M | $3.3M |
| Operating income | -$34.6M | $34.7M | -$26.2M | -$27.5M | -$22.8M | -$40.3M | -$42.2M | -$37.7M |
| Net income | -$52.9M | $15.1M | -$38.6M | -$39.3M | -$32.9M | -$46.7M | -$43.9M | -$37.3M |
| EPS (diluted) | $-1.84 | $0.52 | $-1.34 | $-1.28 | $-1.14 | $-1.71 | $-1.64 | $-1.41 |
| EPS (basic) | $-1.84 | $0.54 | $-1.34 | $-1.28 | $-1.14 | $-1.71 | $-1.64 | $-1.41 |
| Operating margin | -$136 | $45 | -$118 | -$99 | -$76 | -$368 | -$588 | -$1.1K |
| Net margin | -$207 | $20 | -$174 | -$142 | -$109 | -$425 | -$612 | -$1.1K |
Balance sheet
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $329.7M | $364.4M | $353.1M | $335.2M | $422.1M | $483.8M | $493.4M | $427.4M |
| Stockholders' equity | $12.7M | $37.2M | -$29.4M | -$44.7M | $34.0M | $70.9M | $84.4M | $9.9M |
| Total current assets | $316.1M | $350.2M | $330.6M | $291.9M | $363.1M | $431.9M | $448.7M | $367.4M |
| Total current liabilities | $41.7M | $38.6M | $38.1M | $35.5M | $44.0M | $45.4M | $43.9M | $40.4M |
| Cash & equivalents | $248.5M | $238.2M | $109.8M | $44.3M | $98.6M | $123.1M | $191.6M | $71.8M |
| Accounts receivable | $25.7M | $33.9M | $75.7M | $21.4M | $17.9M | $40.8M | $12.2M | $9.0M |
| Property, plant & equipment | $1.3M | $1.4M | $1.5M | $1.6M | $1.7M | $1.8M | $1.7M | $1.8M |
| Other non-current assets | $256.0K | $256.0K | $256.0K | $256.0K | $256.0K | $256.0K | $256.0K | $256.0K |
| Accounts payable | $7.5M | $3.9M | $2.9M | $3.3M | $6.1M | $4.0M | $3.6M | $4.9M |
| Accrued liabilities | $32.1M | $32.7M | $33.2M | $30.2M | $36.0M | $39.5M | $38.4M | $33.7M |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $29.0K | $28.0K | $28.0K | $28.0K | $30.0K | $30.0K | $30.0K | $27.0K |
| Retained earnings | -$825.4M | -$772.6M | -$822.2M | -$837.3M | -$798.7M | -$759.3M | -$737.5M | -$704.7M |
| Accumulated other comprehensive income (loss) | -$146.0K | -$24.0K | $47.0K | -$6.0K | $161.0K | $305.0K | $759.0K | -$415.0K |
Cash flow
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.9M | $98.0M | -$27.4M | -$40.2M | -$10.7M | -$66.7M | -$10.1M | -$21.3M |
| Investing cash flow | $35.0M | $73.5M | $103.3M | $36.4M | $14.8M | -$29.4M | $58.6M | -$2.4M |
| Financing cash flow | $1.2M | -$43.1M | -$10.4M | -$50.5M | -$28.6M | $27.6M | $71.2M | $41.9M |
| Free cash flow | -$25.9M | $98.0M | -$27.4M | -$40.3M | -$10.7M | -$66.9M | -$10.1M | -$21.4M |
| Capital expenditures | $17.0K | $1.0K | $12.0K | $39.0K | $35.0K | $263.0K | $35.0K | $33.0K |
| Depreciation & amortization | $130.0K | $131.0K | $140.0K | $142.0K | $146.0K | $145.0K | $144.0K | $154.0K |
| Share-based compensation | $14.2M | $8.5M | $9.2M | $9.2M | $9.2M | $8.2M | $8.2M | $7.5M |
| Purchases of investments | $0 | $0 | $19.7M | $54.2M | $122.5M | $120.9M | $51.3M | $149.2M |
| Share repurchases | $0 | $3.4M | $9.7M | $51.1M | $4.4M | $456.0K | $0 | $0 |
| Tax withholding on stock comp | $0 | $0 | $0 | $0 | $1.5M | $0 | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M |
| Operating income | $47.9M | -$114.9M | -$164.4M | -$115.2M | -$56.8M |
| Net income | -$13.2M | -$145.2M | -$163.6M | -$128.7M | -$57.8M |
| EPS (diluted) | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 |
| EPS (basic) | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 |
| Operating margin | $20 | -$126 | -$958 | -$1.1K | -$90 |
| Net margin | -$6 | -$159 | -$954 | -$1.3K | -$91 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M | $643.1M |
| Stockholders' equity | $37.2M | $70.9M | $88.1M | $262.1M | $356.4M |
| Total current assets | $350.2M | $431.9M | $406.8M | $447.2M | $553.9M |
| Total current liabilities | $38.6M | $45.4M | $37.4M | $26.1M | $16.1M |
| Cash & equivalents | $238.2M | $123.1M | $36.0M | $71.3M | $495.7M |
| Accounts receivable | $33.9M | $40.8M | $6.9M | $1.4M | $876.0K |
| Property, plant & equipment | $1.4M | $1.8M | $2.1M | $2.1M | $2.3M |
| Other non-current assets | $256.0K | $256.0K | $256.0K | $256.0K | $256.0K |
| Accounts payable | $3.9M | $4.0M | $4.7M | $2.8M | $1.7M |
| Accrued liabilities | $32.7M | $39.5M | $31.0M | $21.6M | $12.9M |
| Other current liabilities | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $28.0K | $30.0K | $27.0K | $29.0K | $28.0K |
| Retained earnings | -$772.6M | -$759.3M | -$614.1M | -$450.5M | -$321.8M |
| Accumulated other comprehensive income (loss) | -$24.0K | $305.0K | -$797.0K | -$5.2M | -$422.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $19.7M | -$135.3M | -$120.8M | -$73.6M | -$45.9M |
| Investing cash flow | $228.0M | $95.4M | $144.8M | -$394.8M | $38.8M |
| Financing cash flow | -$132.6M | $127.1M | -$59.3M | $44.0M | $252.3M |
| Free cash flow | $19.6M | -$135.7M | -$121.6M | -$74.0M | -$47.3M |
| Capital expenditures | $87.0K | $358.0K | $807.0K | $358.0K | $1.4M |
| Depreciation & amortization | $559.0K | $606.0K | $652.0K | $675.0K | $619.0K |
| Share-based compensation | $36.1M | $34.0M | $33.2M | $27.4M | $15.3M |
| Purchases of investments | $196.4M | $380.4M | $303.9M | $802.5M | $118.7M |
| Share repurchases | $68.6M | $456.0K | $50.0M | $0 | $0 |
| Tax withholding on stock comp | $1.5M | $7.5M | $0 | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ANAB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 11:47 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-03-12 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-03-12 | View on SEC.gov → |
| 2026-07-30 | 8-K | 2026-07-28 | View on SEC.gov → |
| 2026-06-22 | 8-K | 2026-06-15 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-05-29 | 8-K | 2026-05-29 | View on SEC.gov → |
| 2026-05-21 | 8-K | 2026-05-18 | View on SEC.gov → |
| 2026-05-13 | 4 | 2026-05-11 | View on SEC.gov → |
| 2026-05-13 | 4 | 2026-05-11 | View on SEC.gov → |
Recent news
Headlines about ANAB (AnaptysBio, Inc.). Links open the publisher — we don’t host full articles.
-
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance · 2026-09-01 -
GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control
Yahoo Finance · 2026-08-17 -
AnaptysBio: The Royalty Waterfall Is About To Reverse
Seeking Alpha · 2026-07-29 -
What Makes AnaptysBio (ANAB) an Investment Bet?
Yahoo Finance · 2026-07-14 -
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Yahoo Finance · 2026-05-21 -
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
Yahoo Finance · 2026-05-19 -
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Yahoo Finance · 2026-05-14 -
AnaptysBio GAAP EPS of -$1.84 misses by $1.04, revenue of $25.56M beats by $6.69M
Seeking Alpha · 2026-05-12
No headlines in this category right now — try “All”.